Rallybio/RLYB

$1.76

1.79%
-
1D1W1MYTD1YMAX

About Rallybio

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.

Ticker

RLYB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Martin Mackay

Employees

43

Headquarters

New haven, United States

Rallybio Metrics

BasicAdvanced
$66.55M
Market cap
-
P/E ratio
-$1.84
EPS
-
Beta
-
Dividend rate
$66.55M
$9.14
$1.23
1.61M
12.392
-50.37%
-54.13%
-54.02%
0.627
0.627
12.44%

What the Analysts think about Rallybio

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 5 analysts.
615.91% upside
High $20.00
Low $8.00
$1.76
Current price
$12.60
Average price target

Rallybio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-20.2M
10.38%
Profit margin
0%
-

Rallybio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.23%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.43
-$0.46
-$0.45
-$0.50
-
Expected
-$0.49
-$0.48
-$0.51
-$0.45
-$0.46
Surprise
-11.47%
-3.74%
-11.52%
11.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Rallybio stock?

Rallybio (RLYB) has a market cap of $66.55M as of April 22, 2024.

What is the P/E ratio for Rallybio stock?

The price to earnings (P/E) ratio for Rallybio (RLYB) stock is 0 as of April 22, 2024.

Does Rallybio stock pay dividends?

No, Rallybio (RLYB) stock does not pay dividends to its shareholders as of April 22, 2024.

When is the next Rallybio dividend payment date?

Rallybio (RLYB) stock does not pay dividends to its shareholders.

What is the beta indicator for Rallybio?

Rallybio (RLYB) does not currently have a Beta indicator.

What is the Rallybio stock price target?

The target price for Rallybio (RLYB) stock is $12.6, which is 615.91% above the current price of $1.76. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Rallybio stock

Buy or sell Rallybio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing